Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osemitamab - Transcenta Holding

Next Previous
Drug Profile

Osemitamab - Transcenta Holding

Alternative Names: Claudin18.2 monoclonal antibody - Mabspace Biosciences; second generation Claudin 18.2 antibody - Transcenta Holding; TST-001; TST001 - Claudin18.2 monoclonal antibody

Latest Information Update: 19 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transcenta Holding
  • Developer Henan Cancer Hospital; Transcenta Holding
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Gastric cancer; Solid tumours
  • Phase I/II Pancreatic cancer

Most Recent Events

  • 17 Apr 2026 Efficacy data from preclinical studies in Pancreatic cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 17 Apr 2026 Pharmacodynamics data from preclinical studies in Pancreatic cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 05 Dec 2025 Updated efficacy data from a phase I/II trial in Solid tumours released by Transcenta Holding

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top